Blood Collection Tubes Market Analysis

The blood collection tubes market size is estimated at USD 2.24 billion by 2024 and is expected to reach USD 3.13 billion by 2029, growing at a CAGR of 6.85% during the forecast period (2024-2029).

The pandemic has had an impact on the market. In February 2021, the World Health Organization stressed the importance of preparedness and rapid response and outlined key actions and measures that blood services should take to mitigate potential risks to the safety and adequacy of blood supply during the pandemic. Moreover, according to a study published in the National Library of Medicine Blood Center in April 2022, more attention should be paid to launching initiatives and policies to increase the country's blood supply, as the virus does not pose a direct threat to blood safety. Similarly, initiatives such as increasing product launches such as home blood collection tubes are expected to boost market growth during the forecast period. For instance, in December 2021, Ethos Laboratories launched Tru-Immune, a finger-prick self-collection kit for COVID-19 neutralizing antibody testing. The launch of such products, which provide a safe at-home blood collection procedure, is expected to increase the adoption of such products, however, currently, the market has lost some of its appeal as the pandemic subsides, hence the market is expected to maintain steady growth over the forecast period of the study.

The major factors driving the growth of the market are the increase in the geriatric population and the rising incidence of chronic diseases. Moreover, the increasing number of surgeries due to various conditions and accidents is also driving the market. The increasing burden of these diseases is expected to have a significant impact on the market, as with the increasing burden of inflammatory and infectious diseases, awareness of these diseases is also increasing, and the demand for blood collection is expected to have a significant and positive impact on the growth of the segment. For instance, according to the October 2022 update of the World Health Organization, the global incidence of tuberculosis (TB) is expected to be around 10.6 million in 2021, of which 1.2 million are children. Similarly, the increase in the number of surgeries is expected to boost the market growth. According to the data updated in August 2022 by the Organization for Economic Cooperation and Development, the number of surgeries (in thousands) in 2021 in some European countries such as Portugal, Denmark, Ireland, and Norway include 94.87, 49.33, 32.84, 21.5, respectively. Such a large number of surgeries in developed European countries will lead to an increase in the demand for blood collection tubes, driving market growth. Therefore, the above factors are expected to increase market growth.
In addition, agreements between market players are another factor in market growth. For example, in November 2021, Q-Sera Pty Ltd signed an exclusive agreement with Terumo Corporation to manufacture and sell Q-Sera's RAPClot rapid serum collection tube technology in Japan. Such agreements are expected to increase the supply of products in the market, thereby promoting market growth during the forecast period.

However, the risk of infection due to unhygienic blood transfusion is a drawback to market growth.

Blood Collection Tube Market Trends

The EDTA Tube segment is expected to occupy a significant market share during the forecast period

EDTA tubes are widely used in clinical hematology and various types of blood cell testing instruments. EDTA works by binding calcium in the blood and preventing blood from clotting. These tubes are used in most hematological procedures such as ablative treatments, blood transfusions, etc. It is mainly used for complete blood counts. A research article published in the National Library of Medicine in October 2021 showed that EDTA as an anticoagulant is superior to citrate in stabilizing platelet EV concentrations. In addition, since the stability of platelet EVs in one freeze-thaw cycle was comparable between the two anticoagulants, it is recommended to use EDTA as an anticoagulant to establish biobanks for EV research.
The major share of this segment can be attributed to the aging population and the increase in widespread diseases such as diabetes. The prevalence of diabetes has increased in recent years and is expected to rise further in the future. For example, according to a December 2021 report by the International Diabetes Federation, approximately 537 million adults (20-79 years) suffered from diabetes in 2021. The total number of patients with diabetes is expected to rise to 643 million by 2020 and 783 by 2030. The increasing number of patients suffering from various chronic diseases will increase the demand for blood tests by 2045, which will help expand the research field.

Similarly, the launch of major market players is another factor for the market growth. For instance, in May 2022, Tethis SpA launched See.d, the first universal blood sample preparer for liquid biopsy analysis. This innovative technology performs fully automated and standardized preparation of blood samples at the time of blood collection. The cellular fraction is gently stabilized on a proprietary nano-coated SBS slide for rare cell detection, including CTCs, while plasma can be used to analyze cell-free content. See.d processes fresh blood collected in EDTA tubes soon after collection (within 4 to 6 hours) to guarantee maximum sample integrity. These developments are expected to boost the use and demand for EDTA blood collection tubes, thereby promoting market growth.